In summary, we have shown that BCL-3 is a potent survival factor in colorectal adenoma-derived and carcinoma-derived cells and propose that the targeting of BCL-3 expression represents a potentially exciting therapeutic opportunity, inhibiting some of the key pathways involved in colorectal tumour progression. The gene discussed is BCL3; the disease is carcinoma.